Related Experiment Video
Updated: Jul 1, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Late diagnosis of late onset Fabry disease
Timothy G Scully1, Heather Chalinor1, James Theuerle2
1Cardiology, Austin Health, Heidelberg, Victoria, Australia.
Insights
Early genetic screening and advanced imaging are crucial for diagnosing left ventricular hypertrophy (LVH). This case reveals how adult-onset Fabry disease, linked to the GLA gene, can mimic other heart conditions, emphasizing timely diagnosis.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Left ventricular hypertrophy (LVH) is a common cardiac finding.
- Initial diagnosis of hypertrophic cardiomyopathy can sometimes overlook underlying genetic causes.
- Delayed diagnosis of conditions like Fabry disease can lead to advanced heart failure.
Purpose of the Study:
- To highlight the diagnostic challenges in patients presenting with LVH.
- To emphasize the importance of genetic testing in unexplained cardiac conditions.
- To showcase the role of advanced imaging in cardiac diagnosis.
Main Methods:
- Transthoracic echocardiogram for initial LVH detection.
- Cardiac MRI to assess myocardial scarring.
- Endomyocardial biopsy for histological examination.
- Genetic testing for GLA gene variants.
Main Results:
- A patient initially diagnosed with hypertrophic cardiomyopathy later developed decompensated heart failure.
- Cardiac MRI revealed extensive scarring, leading to a presumptive diagnosis of cardiac amyloidosis.
- Endomyocardial biopsy was non-diagnostic for the cause of LVH.
- Genetic testing identified a GLA gene variant, indicating adult-onset Fabry disease.
Conclusions:
- Genetic testing is essential for diagnosing inherited cardiomyopathies.
- Advanced imaging modalities like cardiac MRI aid in characterizing cardiac pathology.
- Early identification of Fabry disease through genetic screening can prevent disease progression and improve patient outcomes.
Abstract:
A male in his 50s initially presented with left ventricular hypertrophy (LVH) identified on transthoracic echocardiogram. He was diagnosed with hypertrophic cardiomyopathy without any further investigations. He later presented in his 70s with decompensated heart failure. A cardiac MRI was performed that demonstrated extensive scarring, and the patient was labelled with a presumptive diagnosis of cardiac amyloidosis. An endomyocardial biopsy demonstrated extensive myocyte hypertrophy and fibrosis but was non-diagnostic in identifying a cause of the LVH. Genetic testing revealed that the patient had a genetic variant in the GLA gene, which encodes for the α-galactosidase A enzyme that is known to be associated with adult onset of Fabry disease. This case highlights the importance of early incorporation of genetic screening and advanced imaging modalities in patients presenting with LVH.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Lysosomal Hydrolases
